AGAnchel González-Barriga

Anchel González-Barriga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anchel González-Barriga has a total of 3 co-authors. Here are the top co-authors by number of shared publications:

  • Arturo López-Castel

    Human Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Vicent Andrés Estellés, 19, Valencia 46100, Spain; INCLIVA Biomedical Research Institute, Av. Menendez Pelayo 4, Valencia 46010, Spain; Ciberer Isciii, Av. Monforte de Lemos 3-5, Madrid 28029, Spain

    1 shared publication
  • Jorge Espinosa-Espinosa

    Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, 46100 Burjasot, Spain

    1 shared publication
  • Ruben Artero

    University of Valencia

    1 shared publication

Latest Publications

  • Open Access

    Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies

    by Jorge Espinosa-Espinosa, Anchel González-Barriga, Arturo López-Castel, Rubén Artero

    Omics studies are crucial to improve our understanding of myotonic dystrophy type 1 (DM1), the most common muscular dystrophy in adults. Employing tissue samples and cell lines derived from patients and animal models, omics approaches have revealed the myriad alterations in gene and microRNA expression, alternative splicing, 3′ polyadenylation, CpG methylation, and proteins levels, among others, that contribute to this complex multisystem disease. In addition, omics characterization of drug candidate treatment experiments provides crucial insight into the degree of therapeutic rescue and off-target effects that can be achieved. Finally, several innovative technologies such as single-cell sequencing and artificial intelligence will have a significant impact on future DM1 research.